Bradykinin and Neurotensin Analogues as Potential Compounds in Colon Cancer Therapy.
bradykinin
colorectal cancer
neurotensin
peptides
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
received:
31
03
2023
revised:
29
05
2023
accepted:
30
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Colorectal cancer (CRC) is one of the most lethal malignancies worldwide, so the attempts to find novel therapeutic approaches are necessary. The aim of our study was to analyze how chemical modifications influence physical, chemical, and biological properties of the two peptides, namely, bradykinin (BK) and neurotensin (NT). For this purpose, we used fourteen modified peptides, and their anti-cancers features were analyzed on the HCT116 CRC cell line. Our results confirmed that the spherical mode of a CRC cell line culture better reflects the natural tumour microenvironment. We observed that the size of the colonospheres was markedly reduced following treatment with some BK and NT analogues. The proportion of CD133+ cancer stem cells (CSCs) in colonospheres decreased following incubation with the aforementioned peptides. In our research, we found two groups of these peptides. The first group influenced all the analyzed cellular features, while the second seemed to include the most promising peptides that lowered the count of CD133+ CSCs with parallel substantial reduction in CRC cells viability. These analogues need further analysis to uncover their overall anti-cancer potential.
Identifiants
pubmed: 37298595
pii: ijms24119644
doi: 10.3390/ijms24119644
pmc: PMC10253536
pii:
doi:
Substances chimiques
Bradykinin
S8TIM42R2W
Neurotensin
39379-15-2
AC133 Antigen
0
Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Am J Physiol. 1991 Sep;261(3 Pt 1):G497-503
pubmed: 1887896
Int J Mol Sci. 2014 Jul 08;15(7):12094-106
pubmed: 25007066
Oncogenesis. 2013 Sep 16;2:e71
pubmed: 24042735
Genes Cancer. 2014 Jul;5(7-8):240-249
pubmed: 25221642
Can J Physiol Pharmacol. 2002 Apr;80(4):275-80
pubmed: 12025961
Peptides. 1985 Mar-Apr;6(2):161-4
pubmed: 4034408
Nature. 2010 May 27;465(7297):492-6
pubmed: 20505730
J Pept Sci. 2006 Dec;12(12):775-9
pubmed: 17131289
Clin Cancer Res. 2002 May;8(5):1280-7
pubmed: 12006549
Int J Oncol. 2018 Feb;52(2):599-612
pubmed: 29207035
Cell Mol Gastroenterol Hepatol. 2022;13(2):501-516
pubmed: 34560309
Eur J Pharmacol. 2001 Oct 19;429(1-3):161-76
pubmed: 11698039
Biol Chem. 2008 Sep;389(9):1225-33
pubmed: 18713009
J Cell Physiol. 2019 Mar;234(3):2851-2865
pubmed: 30132865
Int J Cancer. 1999 Jan 29;80(3):448-54
pubmed: 9935189
Eur J Pharmacol. 2013 Sep 15;716(1-3):54-60
pubmed: 23500196
Int Immunopharmacol. 2020 Feb 24;82:106305
pubmed: 32106060
J Neurosci. 1999 Jan 1;19(1):503-10
pubmed: 9870978
Int J Oncol. 2019 Jul;55(1):223-242
pubmed: 31180528
J Allergy Clin Immunol. 2016 Aug;138(2):359-66
pubmed: 27246526
PLoS One. 2012;7(9):e44714
pubmed: 23028588
Proc Natl Acad Sci U S A. 1988 May;85(9):3245-9
pubmed: 2896357
J Mol Med (Berl). 2009 Nov;87(11):1097-104
pubmed: 19727638
World J Biol Chem. 2014 May 26;5(2):130-40
pubmed: 24921004
Peptides. 2006 Oct;27(10):2424-33
pubmed: 16904238
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
Cancer Res. 1992 Jan 1;52(1):24-31
pubmed: 1309227
Expert Opin Ther Targets. 2018 Jan;22(1):31-44
pubmed: 29168929
Int J Cancer. 2001 May 15;92(4):503-9
pubmed: 11304684
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4608-13
pubmed: 11930011
PLoS One. 2010 Sep 10;5(9):
pubmed: 20844765
J Cardiovasc Pharmacol. 2002 Apr;39(4):478-87
pubmed: 11904521
Int J Biochem Cell Biol. 2013 May;45(5):952-9
pubmed: 23395631
Pharmacol Rev. 2005 Mar;57(1):27-77
pubmed: 15734727
J Pharm Pharmacol. 1991 Dec;43(12):887-8
pubmed: 1687595
Adv Exp Med Biol. 2009;611:353-4
pubmed: 19400223
Peptides. 2006 Oct;27(10):2434-44
pubmed: 16872719
Int J Oncol. 2017 Jun;50(6):2200-2206
pubmed: 28498396
Curr Cancer Drug Targets. 2010 Nov;10(7):695-704
pubmed: 20578987
Chem Biol Interact. 2004 Dec 7;150(3):283-93
pubmed: 15560894
Nature. 2012 Oct 25;490(7421):508-13
pubmed: 23051748
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Neuropsychopharmacology. 2004 Oct;29(10):1878-88
pubmed: 15150532
Int J Oncol. 2017 Sep;51(3):975-986
pubmed: 28766682
J Urol. 2001 Jun;165(6 Pt 1):2121-5
pubmed: 11371939
Surg Oncol. 1992 Apr;1(2):127-34
pubmed: 1341243
Tumour Biol. 2016 Oct;37(10):14069-14081
pubmed: 27507615
Front Endocrinol (Lausanne). 2013 Jan 17;3:184
pubmed: 23335914
J Pept Sci. 2005 Jul;11(7):436-9
pubmed: 15742339
Bioorg Med Chem Lett. 2006 Apr 15;16(8):2071-5
pubmed: 16464576
Sci Rep. 2022 Nov 8;12(1):19015
pubmed: 36348016
Clin Cancer Res. 2006 Sep 15;12(18):5346-55
pubmed: 17000667
Eur J Pharmacol. 1998 May 1;348(1):1-10
pubmed: 9650825
Prog Neurobiol. 2018 Jun - Aug;165-167:26-50
pubmed: 29355711
ACS Chem Neurosci. 2019 Nov 20;10(11):4535-4544
pubmed: 31589400
Front Endocrinol (Lausanne). 2013 Mar 22;4:36
pubmed: 23526754
J Allergy Clin Immunol. 2009 Dec;124(6):1303-10.e4
pubmed: 19796797
Nature. 2016 May 11;533(7603):411-5
pubmed: 27193687
Peptides. 1990 Sep-Oct;11(5):1041-3
pubmed: 2284196
Int J Cancer. 2012 Apr 15;130(8):1798-805
pubmed: 21630261
Molecules. 2021 Jun 26;26(13):
pubmed: 34206871
Int J Pept Res Ther. 2012 Jun;18(2):117-124
pubmed: 22593719
Acta Biochim Pol. 2009;56(4):641-8
pubmed: 19997652
Int Immunopharmacol. 2002 Dec;2(13-14):1729-39
pubmed: 12489786
J Neurochem. 2008 Nov;107(3):855-70
pubmed: 18778305
ChemMedChem. 2010 Apr 6;5(4):567-74
pubmed: 20222099
Regul Pept. 2011 Oct 10;170(1-3):7-17
pubmed: 21549161
Clin Rev Allergy Immunol. 2016 Oct;51(2):152-61
pubmed: 27122021